Clinical Trials for Ovarian Cancer

201407156

Neoadjuvant Chemotherapy Tumor Profiling in Ovarian Cancer: Genomic and Proteomic Analysis Phase N/A Principal Investigator Fuh, Katherine Disease Site Ovary

201710005

NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer. Phase II/III Principal Investigator…

201804169

Cytokine-Induced Depression in Ovarian Cancer: Activation of Kynurenine Pathway Phase N/A Principal Investigator Kuroki, Lindsay Disease Site Other Female Genital; Ovary

201806120

Ovation II: Protocol 201-17-201: A Phase I/II study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly…

201910142

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Phase III Principal Investigator Thaker, Premal Disease Site Ovary…

202001099

A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer Phase II Principal Investigator Mutch, David Disease Site Other Female Genital; Ovary Learn more about this study at: clinicaltrials.gov

202002046

ENGOT-ov50 / INNOVATE-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer Phase III (Cancer Control) Principal Investigator Thaker, Premal Disease Site Cervix;…

202002107

A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b Phase I/II (Cancer Control) Principal Investigator Thaker, Premal Disease Site Other Female Genital; Ovary Learn…

202103080

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer Phase III (Cancer Control) Principal Investigator Thaker, Premal Disease Site Ovary Learn more about…